Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib in Advanced Biliary Tract Cancer With IDH1 Mutations
NCT07282262Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivosidenib in biliary tract cancer (BTC), sponsored by Peking Union Medical College Hospital. Started May 2024; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07282262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282262.